Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BiomX Inc. COmmon Stock (NY:PHGE)

0.4030 +0.0130 (+3.33%)
Streaming Delayed Price Updated: 12:19 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BiomX Inc. COmmon Stock

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says
BiomX's breakthrough phage therapy delivers positive results in diseases that stumped Big Pharma for decades (NYSE: PHGE)* 
Via News Direct
Exposures Product Safety
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
Via AB Newswire
Exposures Product Safety
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
From BiomX Inc.
Via Business Wire
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
From BiomX Inc.
Via Business Wire
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
From BiomX
Via Business Wire
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
From BiomX Inc.
Via Business Wire
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
From BiomX Inc.
Via Business Wire
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
From BiomX Inc.
Via Business Wire
BiomX Announces Corporate Restructuring
From BiomX Inc.
Via Business Wire
BiomX Announces Publication in the Journal, Bioinformatics
From BiomX Inc.
Via Business Wire
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
From BiomX Inc.
Via Business Wire
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
From BiomX Inc.
Via Business Wire
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
From BiomX Inc.
Via Business Wire
BiomX Presenting at Three Upcoming Investor Conferences
From BiomX Inc.
Via Business Wire
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
From BiomX Inc.
Via Business Wire
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
From BiomX Inc.
Via Business Wire
BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference
From BiomX Inc.
Via Business Wire
BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates
From BiomX Inc.
Via Business Wire
BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021
From BiomX Inc.
Via Business Wire
BiomX to Present at Upcoming April Investor Events
From BiomX Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.